IngentaConnect Table Of Contents: Value in Health

>The Economic Burden of Alzheimer's Disease to Medicaid in California (Medi-Cal)
pp. 25-25(1)
Authors: Menzin J.; Lang K.; Friedman M.; Neumann P.

>Cost Impact of Using Olanzapine at a Veterans Affairs Medical Center
pp. 25-25(1)
Authors: Weiss M.; McCollum M.

>Comparison of Sumatriptan (Imitrex®) and Over-the-Counter (OTC) Medication use According to Migraine Severity
pp. 26-26(1)
Authors: Yuran T.; Schaffer M.; Lofland J.; Johnson N.; Johnson K.

>SSRI Antidepressant use Patterns and Their Relation to Clinical Global Impressions Scores: A Naturalistic Study
pp. 26-26(1)
Authors: Hylan T.; Meneades L.; Crown W.; Sacristan J.; Gilaberte I.; Montejo A.

>SSRI Antidepressant use in Primary Care in the United Kingdom: A Multivariate Analysis
pp. 26-27(2)
Authors: Hylan T.; Donoghue J.; Dunn R.; Ozminkowski R.

>Evaluation of Antidepressant Utilization Patterns and Associated Depression Diagnoses Among Patients in A National Managed Care Organization
pp. 27-27(1)
Authors: Way K.; Brintnall E.; Whitehouse D.; Young C.; Gregor K.; Hughes T.

>Economic Outcomes of Carotid Endrterectomy for Stroke
pp. 27-28(2)
Authors: Patterson H.; Seltzer J.

>Cost-Effectiveness and Economic Efficiency: The Case of Statin Therapy in Secondary Prevention of Cornary Heart Disease
pp. 28-28(1)
Authors: Russell M.; Huse D.; Miller J.; Hartz S.

>Adherence to Hypertension Therapy: The Effect of Initial Drug Choice
pp. 28-28(1)
Authors: Caro J.; Speckman J.; Salas M.; Raggio G.; Jackson J.

>Withdrawn
pp. 28-29(2)

>Effect of Compliance on Health and Economic Outcomes: Role of Conjugated Estrogen on Depression and Cardiovascular Disorders.
pp. 29-29(1)
Authors: Heaton A.; Flinner A.; Martin S.; Emmett K.; Buatti M.

>Confounding by Indication in Calcium Channel Blocker Treatment of Hypertension or Angina
pp. 29-30(2)
Authors: Mallick R.; Leader S.; Roht L.

>Treatment Choice and the Incidence and Economic Intensity of Hospital Inpatient Use by Depressed Patients
pp. 30-30(1)
Authors: Croghan T.; Kniesner T.; Melfi C.; Klein E.

>Medical Costs of Venlafaxine Versus Tricyclic or Tetracyclic Antidepressant Therapy After Switching from Selective Serotonin Reuptake Inhibitors
pp. 30-30(1)
Authors: Griffiths R.; Sullivan E.; Frank R.; Herbert R.; Strauss M.; Goldman H.

>Cost-Effectiveness Evaluation of New Antipsychotics
pp. 30-31(2)
Authors: Launois R.; Knapp M.; Graf v.n. Schulenburg M.; Toumi M.

>Comparison of Standard Gamble, Time Trade-Off, and Visual Analog Scale Scores for Hypothetical Stroke Health States Using a Computer-Based Program
pp. 31-31(1)
Authors: Namjoshi M.; Taylor T.

>Changes in Sexual Function and Bother in Men Treated for Prostate Cancer: Results from the Capsure™ Database
pp. 31-32(2)
Authors: Flanders S.; Henning J.; Lubeck D.; Pasta D.; Stoddard M.; Litwin M.

>Medical and Economic Relevance of Screening of Stroke Risk by Employees
pp. 32-32(1)
Authors: Hansen N.; Lipinski J.; Rappenhöner B.; Bachinger A.; Rychlik R.

>Cost of Italian Hypertensive Patient: A Feasibility Study from the Pandora Project
pp. 32-32(1)
Authors: Berto P.; Degli Esposti E.; Buda S.; Sturani A.; Reggio S.

>Development and Cross-Validation of a Comorbidity Index for a Stroke Population
pp. 33-33(1)
Authors: Ricci J.; Martin B.

>Evaluation of The Costs of Coronary Heart Disease in Belgium
pp. 33-33(1)
Authors: Annemans L.; Backer W.; Rompay W.; Closon M.

>In-Hospital Survival of Congestive Heart Failure Patients Treated with Dobutamine Or Milrinone
pp. 33-34(2)
Authors: Weycker D.; Simons W.

>Preventing Cardiovascular Disease: Is Primary Prevention with Pravastatin Worth the Money?
pp. 34-34(1)
Authors: Caro J.; Payne K.; Klittich W.; Getsios D.; Shepherd J.; Pettit D.

>Torsemide and Furosemide in the Treatment of the Edema of Heart Failure: Interim Results of a Randomized Effectiveness Trial
pp. 34-34(1)
Authors: Murray M.; Stroupe K.; Pierson W.; Heyman E.; Minick S.; Tierney W.; Brater C.

>Economic and Clinical Outcomes Models for the Evaluation of Drug Therapy Strategies in Treatment of Gerd
pp. 35-35(1)
Authors: McGhan W.; Smith M.; Crawley J.

>Noncompliance with Dosing Instructions and Gastrointestinal Outcomes Associated with Alendronate for Osteoporosis in a Large HMO
pp. 35-35(1)
Authors: Ettinger B.; Schein J.; Pressman A.

>Cost-Effectiveness of Proton Pump Inhibitors in Gastric Ulcer
pp. 36-36(1)
Authors: Ikeda S.; Ikegami N.

>Prospective Economic Evaluation in a Phase IIIb Renal Transplant Clinical Trial
pp. 36-36(1)
Authors: Arnold R.; Pettit K.; DiCesare J.; Fastenau J.; Kaniecki D.

>Withdrawn
pp. 36-36(1)

>Predictors of Diagnostic-Related Group Day Outliers in the Medicare End-Stage Renal Disease Population
pp. 37-37(1)
Author: Vilas-Boas I.

>Randomised Prospective Study Comparing Cost-Effectiveness of Teicoplanin and Vancomycin as Second-Line Empiric Therapy for Infection in Neutropenic Patients
pp. 37-37(1)
Authors: Dominguez-Gil A.; Pérez M.; Santos L.; San Miguel J.; Vázquez L.; Vilches P.; Gutierrez N.; García-Siaz R.; Caballero D.

>Willingness to Pay For HIV Prevention: A Study of High-And Low-Risk Groups
pp. 38-38(1)
Author: Flanders S.

>Prescribing Patterns for Treatment of Upper Respiratory Infections
pp. 38-38(1)
Authors: McLaughlin T.; Lalla D.; Kozma C.

>Evaluation of the Cost-Effectiveness of Management Strategies in Cytomegalovirus Infection and Disease
pp. 38-39(2)
Authors: Annemans L.; Mauskopf J.; Richter A.; Chaulay J.; Maclaine G.

>Socio-Economic Relevance of Inpatient Treatment of Skin and Soft Tissue Infections with Tazobactam/Piperacillin 0.5 g/2.0 g in Comparison with Amoxicillin/Clavlanic Acid, Ceftriaxone, and Cefotaxime
pp. 39-39(1)
Authors: Bruchhausen Y.; Rappenhöner B.

>Cost-Effectiveness of Liposomal Daunorubicin Versus Liposomal Doxorubicin in Kaposi Sarcoma
pp. 39-39(1)
Authors: Egan T.; Henry H.

>Improving Clinical Outcomes by Integrating a Normalized, Standardized, Comparative Database into the Process of Clinical Quality Improvement
pp. 40-40(1)
Authors: Bryant D.; Mignardi W.; Seltzer J.

>Disease Management in Hypertension: The Benefits of Meeting Guideline Goals for Blood Pressure
pp. 40-40(1)
Authors: Huse D.; Usry C.; Hartz S.

>A New Paradigm for Assessing Health-Related Quality of Life: A Social-Clinical Model
pp. 40-41(2)
Authors: Wan G.; Counte M.; Cella D.

>A Retrospective Approach to Evaluate Qaly: Estimation of Health Utility Index from the SF-36 in a Managed Care Population
pp. 41-41(1)
Authors: Sengupta N.; Nichol M.

>Health Utilities Index: Further Evidence of Responsiveness
pp. 41-41(1)
Authors: Torrance G.; Feeny D.; Furlong W.; Barr R.; DePauw S.

>Survey Strategies in the Revision of the Guidelines for Economic Evaluation: Canada
pp. 41-42(2)
Authors: Glennie J.; Baladi J.; Berka C.; Hubbard E.; Menon D.; Otten N.; Riviere M.; Torrance G.

>Socioeconomic Efficiency of Prophylaxis of Exacerbations with N-Acetylcysteine in Patients with Chronic Bronchitis
pp. 42-42(1)
Authors: Rappenhöner B.; Bachinger A.; Rychlik R.

>Cost of Preventable Adverse Drug Events in Emergency Department Patients
pp. 42-43(2)
Authors: Dominguez-Gil A.; Bajo A.; Otero M.; Garcia-Gutierrez J.

>Modeling Side Effect Costs from Literature-Based Data: Steroid-Induced Side Effects in Renal Transplantation
pp. 43-43(1)
Authors: Veenstra D.; Stergachis A.; Sullivan S.

>Cost-Benefit Analysis of Recombinant Erythropoietin in Premature Neonates
pp. 43-43(1)
Authors: Wandstrat T.; Maxwell S.

>Incremental Cost-Effectiveness Analysis Comparing 4-Layer Bandage System with and Without Apligraf™ for the Outpatient Treatment of Venous Leg Ulcers
pp. 43-44(2)
Authors: Attard C.; MacNeil P.; Sibbald G.; Torrance G.; Walker V.

>Development of Asthma-Specific Outcomes Measures for Children
pp. 44-44(1)
Authors: Sweeny S.; Lucas D.; Creer T.; French D.

>Poor Adherence to Hypertension Treatment Guidelines: An Analysis of Therapeutic Choices
pp. 44-45(2)
Authors: Huse D.; Roht L.; Hartz S.

>The Utilization and Costs of Prescription Drugs in a Texas Medicaid Managed Care Pilot Program
pp. 45-45(1)
Authors: Johnsrud M.; Lawson K.

>Postmarketing Outcomes Studies: Benefits and Risks
pp. 45-45(1)
Authors: Garfield F.; Caro J.

>Relationship Between Quality of Life, Disease Severity, and Physician Visits in Managed Care Patients with Atopic Dermatitis
pp. 45-46(2)
Authors: Fagan S.; Frech F.; Pettit K.; Bailey E.; Kaniecki D.; Arnold R.; Fivenson D.

>Adherence of Health Care Workers to Hepatitis B Vaccination (HBV) Policy is Influenced by Leadership
pp. 46-46(1)
Author: Sutton E.

>Formulary Impact Decision Modeling in HMG-Coa Reductase Inhibitors
pp. 46-46(1)
Authors: Corey R.; Sung J.

>A Model of Primary Care Treatment of Major Depressive Disorder
pp. 47-47(1)
Authors: Bell E.; Sullivan S.; Ramsey S.; Neil N.; Veenstra D.; Stergachis A.

>Medical and Economic Outcomes of Noncompliance with Dilantin in Adult Medicaid Epileptics
pp. 47-47(1)
Author: Singer M.

>Factors Predicting Potentially Inappropriate Psychotropic Prescribing for the Elderly
pp. 47-48(2)
Authors: Aparasu R.; Mort J.

>Testing the Reliability of Generic Quality-of-Life Measures in the Study of Multiple Sclerosis
pp. 48-48(1)
Authors: Holmes J.; Kind P.

>The EuroQol in Parkinson's Disease Research: Rated Current Health vs. Population-Derived Health State Preferences
pp. 48-48(1)
Authors: Chrischilles E.; Rubenstein L.; Voelker M.

>Factors Influencing the Decision to Treat Serum Lipid Disorders by Drug Therapy in the Primary Care Venue
pp. 49-49(1)
Authors: Yuan Y.; Silbert G.; Doyle J.; Copeland K.

>An Analysis of the Economics of Hypertension
pp. 49-49(1)
Authors: West D.; Corey R.

>How Does Gender Affect Pharmacotherapy Treatment Decisions for Hypercholesterolemia/Hyperlipidemia?
pp. 49-50(2)
Authors: Copeland K.; Yuan Y.

>Empirical Analysis of the Cost-Efficiency of HMG-CoA Reductase Inhibitors
pp. 50-50(1)
Author: Foley J.

>Pharmaceutical Costs of Patient Non-Adherence to Lipid-Lowering Drug Therapy
pp. 50-50(1)
Authors: Beck P.; Downey W.; Butler-Jones D.; Lueck L.

>Development of a Decision-Analytic Model of Stroke Care in US and Europe
pp. 50-51(2)
Authors: Chambers M.; Koch P.; Hutton J.

>Economic Evaluation of Torasimide in Congestive Heart Failure in Germany
pp. 51-51(1)
Authors: Spannheimer A.; Goertz A.

>Readiness to Comply and Outcomes of Antihypertensive Therapy
pp. 51-51(1)
Authors: Garfield F.; Willey C.; Stafford J.; Redding C.; Caro J.

>Medical and Economic Outcomes in Patients Treated with Diltiazem or Digoxin for Atrial Fibrillation: A Database Analysis
pp. 52-52(1)
Authors: Windisch P.; Vlasses P.; Jankowskr L.

>Study of Hypertensive Prescribing Practices
pp. 52-52(1)
Authors: Schulman K.; Mehta S.; Gersh B.; Schneider E.; Wilcox C.

>The Impact of Unstable Angina on the use of Medical Resources in Italy
pp. 52-53(2)
Authors: Maggioni A.; Schweiger C.; Tavazzi L.

>One-Year Clinical and Economic Outcomes of Primary Coronary Angioplasty using a National Database
pp. 53-53(1)
Authors: Akhras K.; Lowe L.; Arguelles L.

>Prevalence and Cost of Hospitalizations Due to Angina in the United States using a National Database
pp. 53-53(1)
Authors: Akhras K.; Zhao S.

>Nonparametric Analysis of Cost-Effectiveness Ratios of Pravastatin in Primary Prevention of Cardiovascular Disease
pp. 54-54(1)
Authors: Yuan Y.; Hay J.; LaPuerta P.; Leahy M.

>Study of Procedure Costs and Outcomes Associated with the Pharmacological Treatment of Arterial Disease and Intermittant Claudication in the Department of Claudication in the Department of Defense
pp. 54-54(1)
Authors: Zachry W.; Wilson J.; Lawson K.; Koeller J.

>Smoking Related Costs in the United States
pp. 54-55(2)
Authors: Chua W.; Young T.; Lloyd K.; Sullivan S.

>Lipid Therapy and Cardiovascular Disease: How Many Americans Should be Treated?
pp. 55-55(1)
Authors: Yu W.; Hay J.

>The Impact of Acute Renal Failure on Cost in Elderly Patients with Congestive Heart Failure
pp. 55-55(1)
Authors: Chen Y-T.; Bradford D.; Wang Y.; Seltzer J.; Krumholz H.

>Evaluation of The Costs of Heart Failure in Belgium
pp. 55-56(2)
Authors: Annemans L.; Block P.; Rompay W.; Closon M.

>Convenience Implications of a Single Bolus Thrombolytic
pp. 56-56(1)
Authors: Banks J.; Garfield F.; LaPuerta P.; Spencer-Green G.; Caro J.

>Cost Consequences of Acute Myocardial Infarction in Diabetic Patients-The First Year
pp. 56-56(1)
Authors: O'Brien J.; Shomphe L.; Kavanagh P.; Caro J.

>The Effects of Community-Based Pharmaceutical Care Services on Asthma-Related Quality of Life
pp. 57-57(1)
Authors: Boyd B.; Rascati K.; Lawson K.

>The Economic Implications of Decreased Patient Adherence to Co-Prescribed Diclofenac and Misoprostol (CoRx-D&M) Relative to a Single-Tablet Formulation of Diclofenac/Misoprostol (STF-D/M)
pp. 57-57(1)
Authors: Goldstein J.; Stewart D.; Zabinski R.; Larson L.

>Cost-Utility Relation of the Treatment of Diabetic Foot Lesion with Hyperbaric Oxygene Therapy Versus Standard Therapy
pp. 57-57(1)
Authors: Kilburg A.; Rychlik R.; Rappenhöner B.

>Cost-Effectiveness Analysis of Screening of Type II Diabetes Mellitus in Nonpregnant Adults
pp. 58-58(1)
Authors: Hui R.; Hay J.

>Predicting Hospitalization of Patients with Diabetes Mellitus: An Application of the Bayesian Discriminant Analysis
pp. 58-58(1)
Author: Bhattacharyya S.

>A Managed Care Cost Analysis of the Treatment of Psoriasis
pp. 59-59(1)
Authors: Patterson H.; Gillis S.

>Consequences of High Hematocrit Maintenance Among Hemodialysis Patients.
pp. 59-59(1)
Authors: Shih Y.; Kauf T.

>Comparison of Prevalence Rates of Low Back Disorders Obtained from Two Large National Claims Databases
pp. 59-60(2)
Authors: Dedhiya S.; Zhao S.; Arguelles L.

>Outcomes and Cost-Benefit of Inhaled Corticosteroid Therapy Introduction in Medicaid-Enrolled Asthmatic Children
pp. 60-60(1)
Authors: Balkrishnan R.; Norwood G.

>Bambuterol is a More Cost-Effective Treatment than Salmeterol in Asthma Patients with Nocturnal Symptoms
pp. 60-61(2)
Authors: Crompton G.; Brusasco V.; Eivindson A.; Jamieson A.; Olsson H.; Svensson K.; Ståhl E.

>Validity and Reliability of An American Translation of the St. George's Respiratory Questionnaire
pp. 61-61(1)
Authors: Barr J.; Schumacher G.; Freeman S.; Collette K.

>Cost of Prescription Drugs and Cost of Treatment Failure for Sinusitis
pp. 61-61(1)
Authors: Nadesan B.; Cady P.; Force R.; Force W.; Culbertson V.

>Does the Duration of Pulmonary Rehabilitation Affect the Magnitude of Patient Response?
pp. 61-62(2)
Authors: Barr J.; Schumacher G.; Coleman A.

>A Health Economic Analysis of Fluticasone Propionate, Budesonide, and Beclomethasone Dipropionate for the Treatment of Moderate to Severe Asthma.
pp. 62-62(1)
Authors: Trakas K.; Oh P.; Einarson T.; Shear N.

>Veterans' Satisfaction with H2-Receptor Antagonist (H2RA) Drug Conversion
pp. 62-62(1)

>Efficient Strategies for Osteoporosis Testing
pp. 62-63(2)
Authors: Abbott T.; Mucha L.; Manfredonia D.; Schwartz E.; Berger M.

>SF-12 Osteoarthritis-Specific Health Index: Development and Validation
pp. 63-63(1)
Authors: Gandhi S.; Salmon J.; Zhao S.; Lambert B.; Gore P.; Conrad K.

>Psychometric Evaluation of SF-12 in Osteoarthritis Clinical Trials
pp. 63-64(2)
Authors: Gandhi S.; Salmon J.; Zhao S.; Lambert B.; Gore P.; Conrad K.

>The Responsiveness of Disease-Specific and Generic Health Measures to Changes in the Severity of Rheumatoid Arthritis and to Treatment
pp. 64-64(1)
Authors: Kosinski M.; Ware J.; Zhao S.; Dedhiya S.

>The Responsiveness of Disease-Specific and Generic Health Measures to Changes in the Severity of Osteoarthritis
pp. 64-64(1)
Authors: Zhao S.; Dedhiya S.; Kosinski M.; Ware J.

>Health Care Use in Women Age 45 and Older
pp. 64-65(2)
Authors: Hoerger T.; Eleazer K.; Lindrooth R.; West S.; Ohsfeldt R.

>The Direct Medical Cost of Osteporotic Fractures
pp. 65-65(1)
Authors: Martin B.; Kotzan J.; Reeves J.

>Cost-Effectiveness of Hormone Therapy Versus Calcium Therapy: An Osteoporosis Markov Model
pp. 65-66(2)
Authors: Keys P.; Touchette D.

>Quality of Life and Pharmacoeconomic Aspects of Hormone Replacement Therapy in Post-Menopausal Women—A Canadian Randomized Trial
pp. 66-66(1)
Authors: Haider S.; Petit-Clerc C.; Rioux J.; Lemay A.; Bouchard C.; Fortier M.; Lorrain J.; Scott J.; Reid R.

>Use of Centralized Pharmacy Records in a Managed Care Organization to Determine Effect of Educational Material on Hormone Replacement Therapy Patient Compliance
pp. 66-66(1)
Authors: Chen Y.; McDevitt J.; Wolke O.; Sidorov J.

>Determining Minimally Important Changes (MIC) in Rheumatoid Arthritis (RA) Functional Status
pp. 67-67(1)
Authors: Bagchi I.; Gillis S.; Watrous M.

>Markov Chain Estimation of Life Expectancy of HIV-Infected Patients: Comparison of Two Treatment Alternatives
pp. 67-67(1)
Authors: Bhattacharyya S.; Langley P.; Draugalis J.; Cox E.

>Socioeconomic Relevance of Inpatient Treatment of Intra-Abdominal Infections with Tazobactam/Piperacillin 0.5 g/4.0 g in Comparison with Imipenem/Cilastatin
pp. 67-68(2)
Authors: Bruchhausen Y.; Rappenhöner B.; Kremer B.; Rychlik R.

>Colorectal Cancer Screening: Cost-Effectiveness Analysis from an Italian Viewpoint
pp. 68-68(1)
Authors: Bona M.; Fusillo M.; Grossi E.

>Cost-Effectiveness of Piperacillin-Tazobactam Versus Ceftazidime in Patients with Febrile Neutropenia
pp. 68-68(1)
Authors: Dominguez-Gil A.; Pérez M.; Santos L.; Sanz A.; Rubio C.

>Cost-Effectiveness Analysis of Piperacillin-Tazobactam Versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections
pp. 68-69(2)
Authors: Dominguez-Gil A.; Rubio C.

>Using a Pneumonia-Specific Severity of Illness Model in Assessing Variation in Hospital Length of Stay for Community-Acquired Pneumonia Patients
pp. 69-69(1)
Authors: Tan H.; Koeller J.

>Epoetin Alfa Administered to Academic Health Center Dialysis Patients: Comparison to HCFA Billing Records
pp. 69-69(1)
Authors: Chen C.; Danekas L.; Matuszewski K.; Vlasses P.

>Clinical and Economic Benefits of an Infectious Disease Approval Program
pp. 70-70(1)
Authors: Kinky D.; Fishman N.; Morgan A.; Gibson G.

>The Economic Impact of a Drug Information Service
pp. 70-70(1)
Authors: Kinky D.; Erush S.; Laskin M.; Gibson G.

>The Influence of Case Mix Bias on Costs of Hospitalisation for Lower Respiratory Tract Infection
pp. 70-71(2)
Authors: Peter D.; McMahon A.; White G.; Morris A.; MacDonald T.

>A Health Economic Evaluation of Paclitaxel and Carboplatin Versus Vinorelbine and Cisplatin Combination Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
pp. 71-71(1)
Authors: Sinha N.; Hainsworth J.; Einarson T.; Doyle J.; Arikian S.; Lappas P.

>Information Technology in a Large Multi-Site Outcomes Study
pp. 71-71(1)
Authors: Morlock R.; Ward R.; Nerenz D.; Feng J.; Sadlocha K.

>The Effect of the Louisiana Medicaid Lock-In on Prescription Drug Utilization and Expenditures
pp. 72-72(1)
Authors: Blake S.; Feldhaus J.; Hunter T.; Rappaport H.; Holt G.; Medon P.

>Use of Administrative Data to Create Disease-Specific Datasets for use in Health Economic Studies
pp. 72-72(1)
Authors: Beck P.; Downey W.; Osei W.; Baker M.

>Outcomes Research Interests of a Community Pharmacist Research Network
pp. 72-73(2)
Authors: Wade W.; Spruill W.; Taylor A.; Longe R.

>Prescription Medication use in Older Americans
pp. 73-73(1)
Authors: Mehta S.; Rathore S.; Boyko W.; Schulman K.

>Chronic Care Costs of New Medicare HMO Enrollees: Implications for Disease Management
pp. 73-73(1)
Author: Grannemann T.

>The Value of Medicines: Is there Enough Economic Evidence?
pp. 73-74(2)
Authors: Constenla D.; Munro V.; Hutton J.

>Prenatal Care and Birth Weight in the United States
pp. 74-74(1)
Author: Feng W.

>Evaluation of a Pathway for Providing Pharmaceutical Care
pp. 74-74(1)
Authors: Burgess S.; Perri M.

>The Development of a Patient Outcomes Software for Urologists: CaPSURE POS™
pp. 75-75(1)
Authors: Flanders S.; Henning J.; Roth J.; Stier D.; Grossfeld G.; Carroll P.

>Use of Administrative Databases in Saskatchewan, Canada, for Pharmacoeconomic and Outcomes Research
pp. 75-75(1)
Authors: Downey W.; Stang M.

>The Paradox of League Tables
pp. 75-76(2)
Authors: Caro J.; Klittich W.; Jackson J.

>Application of Pharmacoeconomics and Outcomes Research in Formulary Decision-Making
pp. 76-76(1)
Author: Sarpong D.

>Vox Populi: Stated Preferences for Pharmaceutical Innovations
pp. 76-76(1)
Authors: Bingham M.; Johnson F.; Bell L.

>An Unbiased Method of Pharmaceutical Cost Analysis
pp. 77-77(1)
Authors: Nichol G.; Wells G.; Pham B.

>Implication of Preventing Disease on Life Years Gained (LYG)
pp. 77-77(1)
Authors: Caro J.; Klittich W.

>Surveillance of a New Drug in the United Kingdom
pp. 77-78(2)
Authors: Hartz S.; West S.; Bunten E.

>The Economic Burden of Schizophrenia: Acute General Hospital Costs
pp. 78-78(1)
Authors: O'Brien J.; Shomphe L.; Pietrusewicz M.; Caro J.

>Assessment of Health-Related Quality of Life During Treatment of Opiate Dependence using the Short Form-36
pp. 78-78(1)
Authors: Raisch D.; Garnand D.; Jones M.; Sather M.; Huber A.; Ling W.

>Evaluation of Humanistic Outcomes for Patients on Selective Serotonin Reuptake Inhibitors
pp. 78-79(2)
Authors: Sansgiry S.; Burgoyne D.; Busby C.

>Quality of Life and Adverse Reactions in Depressed Patients Receiving Antidepressant Drugs
pp. 79-79(1)
Authors: Taylor A.; Spruill W.; Longe R.; Wade W.; Ahmed A.

>The Cost of Treating Schizophrenia in the California Medicaid (Medi-Cal) Program
pp. 79-80(2)
Authors: McCombs J.; Nichol M.

>Economic Outcomes of Antidepressant use in a Managed Care Organization
pp. 80-80(1)
Authors: White T.; Nichol M.

>A General Model of the Effects of Alternative Sedative-Hypnotic Agents on the Costs of Motor Vehicle Accidents
pp. 80-80(1)
Authors: Menzin J.; Lang K.; Friedman M.

>Duration of Continuous Therapy Between Atypical and Typical Antipsychotics
pp. 80-80(1)
Authors: Li Z.; Hutchins D.; Johnstone B.; Tunis S.; Coleman T.; Gevirtz F.

>Selective Serotonin Reuptake Inhibitor Utilization Patterns: Consistency Across Research Designs
pp. 81-81(1)
Authors: Hutchins D.; Klein E.; Signa W.; Young C.; Gregor K.

>Month-To-Month Adherence with Antipsychotic Pharmacotherapy: A Comparison Between Atypical and Typical Antipsychotics
pp. 81-81(1)
Authors: Li Z.; Hutchins D.; Johnstone B.; Tunis S.; Coleman T.; Gevirtz F.

>Utlization Review of SSRI Therapy at a Mental Health Managed Care Organization.
pp. 82-82(1)
Authors: Conner T.; Rascati K.; Crawford K.

>Texas Medication Algorithm Project: Feasibility Study of Implementing Medication Algorithms in the Public Mental Health Sector
pp. 82-82(1)
Authors: Crismon M.; Rush A.; Toprac M.; Shon S.; Biggs M.; Shores-Wilson K.; Mason M.

>Developing a Task-Based Instrument to Measure Migraine-Related Productivity
pp. 82-83(2)
Authors: Lee T.; Ramsey S.; Neil N.; Patrick D.; Klastorin T.; Stergachis A.; Sullivan S.

>Schizophrenia Management: Does Managed Care Influence Length of Stay in U.S. Hospitals?
pp. 83-83(1)
Authors: O'Brien J.; Pietrusewicz M.; Pierce D.; Caro J.

>Development of a Self-Administered Outcome Measure for use in an Outpatient Population of Individuals with Schizophrenia
pp. 83-83(1)
Authors: Barr J.; Schumacher G.; Mason E.; Ohman S.; Hanson A.

>A Health Policy analysis of Pharmacotherapy for Major Depressive Disorder in Europe and the Americas
pp. 84-84(1)
Authors: Arikian S.; Einarson T.; Casciano J.; Doyle J.

>Utilization Patterns of Antidepressant Medications in a Patient Population Served by a Primary Care Medical Group
pp. 84-84(1)
Authors: Venturini F.; Sung J.; Nichol M.; Sellner J.

>Monte Carlo Simulation in Health Care Models
pp. 84-85(2)
Authors: Richter A.; Mauskopf J.

>Designing Computer Models to Convey Cost-Effectiveness Analyses Results
pp. 85-85(1)
Authors: Parente S.; Gardner E.; Mohr P.

>Development of Drug Use Performance Models as Measures of Patient Care
pp. 85-85(1)
Authors: Holimon T.; Wurtzbacher J.

>Reconciling Decision Models with the Real World: The Cost-Effectiveness of Erythropoietin for Esrd-Related Anemia
pp. 85-86(2)
Authors: Kauf T.; Shih Y.

>Comparing Computerized Options in Pharmacoeconomics: Spreadsheets, Decision Trees, and Educational Tools: An Open Workshop for Demonstrating Software
pp. 86-86(1)
Author: McGhan W.

>Decision Analysis: What is its Utility for Pharmacoeconomic Analysis?
pp. 86-86(1)
Authors: Caro J.; Migliaccio-Walle K.

>Issues in Developing Economic Models for Managed Care: The Case of Osteoporosis Prevention
pp. 86-87(2)
Authors: Funk Orisini P.; Mullins C.; Weiss S.; Preston K.

>Using Medication History to Measure Indication Bias
pp. 87-87(1)
Authors: Leader S.; Mallick R.

>The Role of Patient Registries in Disease Management and Outcomes Research
pp. 87-87(1)
Authors: Hartz S.; Huse D.

>Using Community Pharmacies to Conduct Outcomes Research
pp. 87-88(2)
Author: Ungar W.

>Construction of a Validated, Normalized, Granular Administrative Database and its use in Clinical Outcomes Improvement, Clinical Research, and Pharmacoeconomic Research
pp. 88-88(1)
Authors: Morris S.; Seltzer J.; Bryant D.

>Disease State Management Tracker: Implementing, Tracking, and Evaluating Clinical Pathways and Outcomes
pp. 88-89(2)
Authors: Ambegaonkar A.; Day D.; Main J.; Lubowski T.; Yamaga C.; Vleet J.

>Strategies for Formulary Comparisons in the Medicaid Managed Care Era
pp. 89-89(1)
Authors: Wurtzbacher J.; Holimon T.

>Prospective, Naturalistic Outcomes Measurement: The Schizophrenia Care and Assessment Program (SCAP)
pp. 89-89(1)
Authors: Haley J.; Russo P.; Johnstone B.; Crown W.

>Evaluating Health Outcomes and Pharmacoeconomic Literature
pp. 89-90(2)
Authors: Fulda T.; Blackburn J.

>Interpreting and Using Costeffectiveness Results
pp. 90-90(1)
Authors: Bala M.; Zarkin G.

>Dissemination of Pharmacoeconomic Results to Managed Care Organizations
pp. 90-90(1)
Authors: Shreve J.; Pedlow K.; Marshall S.; VanDenBos J.

>Outcomes Research in Medication use: Hcfa's Health Care Quality Improvement Program
pp. 90-90(1)
Author: Westrick E.

>Estimating the Costs and Outcomes for Different Disease Management Strategies: A Case Study of Cyomegalovirus Infection and Disease
pp. 91-91(1)
Authors: Mauskopf J.; Annemans L.; Richter A.; Chulay J.; Maclaine G.

>Clinical Intervention Assessment: Implementation of Default Values for Expediting the Calculation of Cost Savings and Cost Avoidances
pp. 91-91(1)
Authors: Mutnick A.; Sterba K.; Vrchoticky T.

>Multivariable Methods for Measuring Treatment Costs in Randomized Trials
pp. 91-92(2)
Authors: Polsky D.; Glick H.

>Use of UB-92S and Medicare Cost Reports in a Large, Multi-Center Randomized Trial: The Pursuit Experience
pp. 92-92(1)
Authors: Davidson-Ray L.; Buell H.; O'Neal B.; McElwee N.; Mark D.

>Discounting Health Benefits in Pharmacoeconomic Analyses: Is it Justified?
pp. 92-92(1)
Authors: Caro J.; Klittich W.

>The use of Patient Self-Reports to Collect Health Care Resource Utilization Data
pp. 92-92(1)
Authors: Crawford B.; Evans C.

>Trade-Off Preferences for Pharmaceutical Development, Marketing, and Outcomes Evaluation
pp. 93-93(1)
Authors: Johnson F.; Desvousges W.

>Practical Applications of the Health Utilities Index
pp. 93-93(1)
Authors: Torrance G.; Walker V.; Rosner A.

>The EuroQoL EQ-5D: An Outcome Measure for use in Clinical and Economic Evaluation
pp. 93-94(2)
Authors: Kind P.; Charro F.